Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
Oslo, Norway, 9 October 2019 - Targovax ASA (OSE: TRVX), announces that clinical data on the company’s lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 6-10, 2019, in Maryland, USA.Title: A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanomaAuthors: